Bristol-myers Squibb

This study tested whether adding an experimental drug (BMS-986012) to standard chemotherapy and immunotherapy could help people with advanced small cell lung cancer live longer without their cancer growing. About 135 newly diagnosed patients took part. The goal was to see if the …

This study tested an experimental drug (BMS-986016) that targets LAG-3, given alone or with another immunotherapy (nivolumab), in people with advanced solid tumors that had spread or couldn't be removed by surgery. The goal was to see if the combination was safe and could shrink …

This study tested three different drug combinations in 292 men with advanced prostate cancer that no longer responds to hormone therapy and has spread. The goal was to see if adding nivolumab (an immunotherapy) to either rucaparib, docetaxel, or enzalutamide could shrink tumors o…

This study tested whether adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy helps people with stage IV non-small cell lung cancer live longer. About 719 patients who had not received prior treatment took part. The goal was to see if the combinatio…

This study tested a new drug, farletuzumab ecteribulin, which targets a protein called folate receptor alpha found on some ovarian cancer cells. It was compared to standard chemotherapy in 106 women whose ovarian, peritoneal, or fallopian tube cancer had stopped responding to pla…

This study tested whether adding a third drug (relatlimab) to a standard two-drug treatment (nivolumab and bevacizumab) is safe and works better for people with advanced liver cancer who haven't had treatment before. 83 adults with advanced liver cancer took part. The goal was to…

This study tested an experimental drug called BMS-986322 in 109 adults with moderate-to-severe plaque psoriasis. The goal was to see if the drug safely reduces skin symptoms like redness, thickness, and scaling. Participants received either the drug or a placebo, and researchers …

This study tested an experimental drug called BMS-986288, given alone or with another drug (nivolumab), in 219 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Researchers also looked …

This study tested the drug nivolumab, alone or with other drugs, in 320 adults with blood cancers like lymphoma and multiple myeloma that had returned or stopped responding to prior treatments. The main goal was to check safety and side effects, especially when nivolumab was comb…

This study looked at the long-term safety of the drug mavacamten in adults with hypertrophic cardiomyopathy, a condition where the heart muscle thickens. About 314 people who had already completed earlier studies took part. The goal was to track any side effects over time, not to…

This study examined how luspatercept works in adults with a type of bone marrow disorder called lower-risk myelodysplastic syndromes (MDS) in China. Researchers wanted to see if the drug helps patients become less dependent on blood transfusions and improves their hemoglobin leve…

This early-phase study tested a fixed-dose combination of two immunotherapy drugs (relatlimab and nivolumab) in 24 Chinese adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, measure drug levels in the body, a…

This study looked at 163 adults with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle is too thick and blocks blood flow) who were treated with the drug mavacamten. Researchers collected information from medical records to see how patients were doing in…

This study tested a drug called mavacamten in 38 Japanese adults with a condition that makes the heart muscle too thick and stiff, blocking blood flow. The goal was to see if the drug could improve heart function and reduce symptoms like shortness of breath and chest pain over 30…

This study tested whether adding immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy helps people with advanced esophageal cancer live longer or keep their cancer from growing. About 970 adults whose cancer could not be removed by surgery or had spread took pa…

This study tested whether the immunotherapy drug nivolumab can help prevent esophageal cancer from coming back after surgery. About 794 people who had surgery for stage II or III cancer received either nivolumab or a placebo. The main goal was to see if nivolumab lengthened the t…

This early-phase study tested a combination of two immunotherapy drugs, relatlimab and nivolumab, in 5 children and young adults whose Hodgkin or non-Hodgkin lymphoma had come back or stopped responding to standard treatments. The main goals were to check safety, find the right d…

This study tested an experimental drug called BMS-986253 combined with two immunotherapy drugs (nivolumab and ipilimumab) in 281 people with advanced cancers like melanoma. The main goals were to check safety and see if the tumors shrank. This is a disease control approach, not a…

This study tested a drug called nivolumab, alone or with other cancer drugs, in 385 people whose colon cancer had returned or spread. The goal was to see if the treatment could shrink tumors in patients whose cancers have a specific genetic feature (MSI-H). The approach uses the …

This study reviewed medical charts of 115 adults in Canada who started taking mavacamten for obstructive hypertrophic cardiomyopathy (oHCM), a condition where the heart muscle thickens and blocks blood flow. Researchers wanted to see how the drug improved symptoms and heart funct…

This early-phase study tested a new experimental drug called BMS-986249, both by itself and together with the immunotherapy nivolumab, in 356 adults with advanced solid tumors (cancers that have spread or cannot be removed). The main goal was to check safety and find the right do…

This study tested a combination of three drugs (nivolumab, trametinib, and ipilimumab) in 325 people with advanced colorectal cancer that had spread and was no longer responding to standard treatments. The goal was to see if these drugs could shrink tumors or slow the cancer's gr…

This study tested adding immunotherapy drugs (nivolumab with or without ipilimumab) to standard chemotherapy before surgery for people with early-stage non-small cell lung cancer. The goal was to see if these combinations could improve outcomes like preventing cancer from coming …

This study tested a combination of three drugs (relatlimab, nivolumab, and either BMS-986205 or ipilimumab) in 229 people with advanced solid tumors that could not be cured. The goal was to see if the triple therapy was safe and could shrink or control the cancer. Participants ha…

This early-stage study tested a new drug called BMS-986315, given alone or with other cancer drugs (nivolumab or cetuximab), in 44 people with advanced solid tumors like head and neck, lung, or kidney cancer. The main goals were to check safety and find the right dose. The study …

This study tested whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) works better than standard chemotherapy for Chinese patients with advanced pleural mesothelioma, a rare cancer of the lung lining. About 102 patients with inoperable disease took part. T…

This study tested whether combining two immunotherapy drugs (nivolumab and ipilimumab) works better than standard chemotherapy (cabazitaxel) or one immunotherapy alone in men with advanced prostate cancer that no longer responds to hormone therapy. A total of 351 men participated…

This study looked at the long-term safety of an experimental drug called BMS-986165 in people with systemic lupus erythematosus (SLE). A total of 261 adults who had already completed an earlier lupus study took part. Researchers tracked side effects, serious health events, and ch…

This study offers continued treatment with elotuzumab and other drugs to multiple myeloma patients who were already benefiting from them in earlier studies but cannot get the drug commercially. 67 participants were enrolled to receive ongoing therapy while researchers tracked sid…

This study tested a combination of two immunotherapy drugs, relatlimab and nivolumab, in 266 adults with advanced liver cancer who had not received immunotherapy before but had already tried other treatments. The goal was to see if the combination could shrink tumors and control …

This study tested whether combining the immunotherapy drug nivolumab with another drug (ipilimumab) or with standard chemotherapy could help people with advanced non-small cell lung cancer live longer without their cancer growing. About 2,700 patients who had not received prior t…

This study tested two immunotherapy drugs, nivolumab and ipilimumab, alone or together, in 657 adults with advanced liver cancer that could not be treated with surgery. The goal was to see if these drugs could shrink tumors and control the disease. Participants received different…

This study tested an experimental drug called BMS-813160, given alone or with chemotherapy and/or the immunotherapy nivolumab, in 332 people with advanced colorectal or pancreatic cancer. The main goals were to check safety and side effects, and to see if the drug combination cou…

This study looked back at medical records of 70 adults in Argentina with a certain type of lung cancer (non-small cell lung cancer) that could be removed with surgery. All patients received a combination of the immunotherapy drug nivolumab and chemotherapy before their surgery. T…

This study tested a new way to give the cancer drug nivolumab: as a shot under the skin instead of through an IV. It included 139 people with advanced cancers like lung, kidney, melanoma, liver, and colorectal cancer. The main goal was to see how the drug behaves in the body and …

This study tested a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 37 Chinese patients whose advanced solid tumors had not responded to prior treatment. The main goals were to check safety and see if the drugs could shrink tumors. While the treatment aims to…

This study tested an experimental drug called BMS-986278 in 403 adults with pulmonary fibrosis, a condition that causes lung scarring and breathing problems. The goal was to see if the drug could improve lung function and check for side effects. Participants took the drug or a pl…

This study tested a new drug called BMS-986408, given alone or with other cancer drugs (nivolumab and ipilimumab), in 68 people with advanced solid tumors that had not responded to other treatments. The main goal was to check safety and find the best dose. This is an early-stage …

This study tested whether the drug deucravacitinib can improve quality of life for adults with moderate-to-severe plaque psoriasis. 180 participants took either the drug or a placebo for 16 weeks. The main goal was to see if more people on the drug reported little to no impact of…

This early-stage study tested a new drug called BMS-986326 in 64 adults with moderate-to-severe atopic dermatitis (eczema). The main goal was to check the drug's safety and how the body processes it. Participants received a single dose of the drug or a placebo, and researchers mo…

This study tested a drug called mavacamten in 580 adults with a type of thickened heart muscle that doesn't block blood flow (non-obstructive hypertrophic cardiomyopathy). The goal was to see if the drug could improve symptoms like shortness of breath and fatigue, and help people…

This study tested an oral medication called deucravacitinib against a placebo in 154 adults with moderate-to-severe scalp psoriasis. The goal was to see if the drug could clear or nearly clear scalp redness, thickness, and scaling by week 16. Participants had stable plaque psoria…

This study looked at 104 people with relapsing-remitting multiple sclerosis (RRMS) who switched their current medication to ozanimod. Researchers wanted to understand the reasons for the switch—such as lack of effectiveness, side effects, or patient preference—and how the switch …

This study looked at whether taking famotidine, a common acid-reducing drug, changes how the body absorbs afimetoran. 32 healthy adults took afimetoran with and without famotidine to compare drug levels. The goal was to see if stomach acid changes affect the drug, not to treat an…

This study looked at 177 people in Japan with a low-risk form of myelodysplastic syndrome (a blood disorder). Researchers collected information on patient characteristics, treatments, and healthcare costs to understand real-world care patterns. No new treatment was tested; the go…

This study looked at how a cancer drug called repotrectinib changes the way the body processes other medications. Thirty healthy adults took a mix of common drugs (like metformin and omeprazole) with and without repotrectinib to see if levels of those drugs changed. The goal was …

This study looked at how the body handles a single dose of the experimental drug BMS-986278 in people with severe kidney problems or those on dialysis, compared to healthy volunteers. The goal was to understand safety and drug levels, not to treat the disease. 27 adults took part…

This study looked at 100 adults with stage III melanoma that could be removed by surgery. Researchers compared two drug combinations given before surgery: nivolumab plus relatlimab versus nivolumab plus ipilimumab. The goal was to understand patient characteristics, treatment pat…

This study in France asked 49 adults with solid tumors how they felt about switching from hospital to home for their immunotherapy treatments. Researchers measured changes in patient satisfaction using a standard questionnaire. The goal was to understand if receiving care at home…

This study looked at how a single dose of repotrectinib stays in the blood of people with moderate or severe liver impairment compared to healthy volunteers. 18 adults took part to help understand if liver function changes drug levels. The results will guide dosing for patients w…

This study looked back at medical records of 418 adults with lower-risk myelodysplastic syndromes (MDS) who had not previously received certain anemia treatments. Researchers examined how doctors prescribed luspatercept, how long patients stayed on it, and what outcomes occurred,…

This study tested a new antibody drug (BMS-986446) in 46 healthy adults to see how well it is absorbed when given as a shot under the skin compared to an IV. The main goal was to measure drug levels in the blood and check for side effects. This early-stage research helps understa…

This study looked at how different versions of an experimental drug, BMS-986460, are absorbed by the body. It involved 85 healthy adult men to check safety and drug levels. The goal was to find the best formulation for future studies.

This study looked at how much of the drug deucravacitinib gets into breast milk and blood after a single dose in healthy women who are breastfeeding. Eight participants provided milk and blood samples over time. The goal was to understand potential infant exposure, not to treat a…

This study looked at how taking the drug admilparant with or without food changes its levels in the blood. Fifty-six healthy adults took the drug under different conditions. The results will help doctors decide the best way to take this medicine.

This study looked at the safety of the drug abatacept in over 38,000 people with rheumatoid arthritis or psoriatic arthritis in Denmark. Researchers used a national health database to track rates of different cancers. The goal was to better understand the drug's long-term safety …

This study looked at 212 adults with advanced non-small cell lung cancer who received the immunotherapy drug nivolumab after chemotherapy. Researchers tracked how many patients were still alive 12, 24, and 36 months after starting treatment. The goal was to see how well the drug …

This early-stage study tested the safety and tolerability of a drug called BMS-986278 in 42 healthy adults. Researchers also checked if the drug affects the heart's electrical activity. The goal was to gather safety information, not to treat any disease.

This study followed 535 people in France with advanced non-small cell lung cancer who were already prescribed nivolumab after at least one round of chemotherapy. Researchers observed how long treatment worked, side effects, and patients' quality of life. The goal was to learn mor…

This study tested the safety and how the body processes a new drug called BMS-986419 in 74 healthy adults. Part 1 looked at side effects and drug levels, while Part 2 checked if the drug affects the heart's electrical activity. No treatment or cure is involved—the goal is simply …

This study followed 450 people with relapsing-remitting multiple sclerosis (RRMS) who were already prescribed ozanimod (Zeposia). Researchers collected real-world data over 3 years to see how long patients stayed on the drug, how it affected their quality of life, and what side e…

This study reviewed medical records of 240 adults in Poland with advanced non-small cell lung cancer who received a combination of two immunotherapy drugs plus chemotherapy as their first treatment. The goal was to see how well the treatment worked in everyday hospital care, not …

This study looked at medical records from 327 adults with advanced kidney cancer to see how two drug combinations (nivolumab plus ipilimumab or pembrolizumab plus lenvatinib) are used in everyday U.S. clinics. Researchers collected information on patient backgrounds, treatment de…

This study looked back at medical records of 260 adults in China with advanced stomach or gastroesophageal junction cancer. All patients received nivolumab as their first treatment. The goal was to see how well the drug worked in real life and how it was used. This was an observa…

This completed study gathered real-world information from 112 adults in France with acute myeloid leukemia (AML) who were in remission and taking oral azacitidine as maintenance therapy. Researchers tracked how long patients stayed relapse-free, overall survival, and treatment pa…

This study looked at the safety of the drug abatacept in over 140,000 people with rheumatoid arthritis or psoriatic arthritis in Sweden. Researchers tracked how many people developed different types of cancer while taking abatacept or other arthritis medications. The goal was to …